Network-1 Technologies, Inc. announced that ILiAD Biotechnologies, LLC reported the first-ever demonstration of protection against B. pertussis (whooping cough) colonization in a Phase 2b Human Challenge study of its BPZE1 vaccine. ILiAD announced that its BPZE1 intranasal pertussis vaccine has met the primary endpoint of protection against nasopharyngeal B. pertussis colonization (p=0.03) in the Phase 2b CHAMPION-1 Study. To date, Network-1 has invested an aggregate of $7,000,000 in ILiAD which represents approximately 6.8% of the outstanding units of ILiAD on a non-fully diluted basis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | 0.00% | -1.03% | -11.93% |
1st Jan change | Capi. | |
---|---|---|
-11.93% | 45.14M | |
+23.22% | 480M | |
+4.03% | 342M | |
+76.84% | 156M | |
-12.98% | 143M | |
-.--% | 139M | |
+152.60% | 99.45M | |
-1.98% | 75.8M | |
+57.43% | 53.29M |
- Stock Market
- Equities
- NTIP Stock
- News Network-1 Technologies, Inc.
- Network-1 Technologies, Inc. Reports First-Ever Demonstration of Protection Against B. Pertussis Colonization in Phase 2B Human Challenge Study of Bpzel Vaccine